May 11, 2020 / 6:30 AM / in 18 days

BRIEF-Astrazeneca Says Enhertu Designated Gastric Cancer Breakthrough Therapy Designation

May 11 (Reuters) - AstraZeneca Plc:

* ASTRAZENECA PLC - ENHERTU DESIGNATED GASTRIC CANCER BTD

* ASTRAZENECA - ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN US FOR HER2-POSITIVE METASTATIC GASTRIC CANCER

* ASTRAZENECA - ENHERTU GRANTED BTD IN GASTRIC CANCER PATIENTS WHO HAVE RECEIVED TWO OR MORE PRIOR REGIMENS INCLUDING TRASTUZUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below